Integrated therapy for HIV and tuberculosis

Table 1 Randomized control trials determining time to initiate ART in HIV-infected patients with TB

Study	TB characteristics	Median CD4 count	Study arms	Mortality difference	Country	ART regimen
(1A) SAPIT 1 Abdool Karim et al. NEJM 2010 [43]	Smear +ve pulmonary TB	150	Integrated vs. sequential	5 vs. 12 deaths/100 PYs 56 % lower in integrated arm	South Africa	ddI, 3TC, EFV
(1B) SAPIT 2 Abdool Karim et al. NEJM 2011 [44]	Smear +ve pulmonary TB	150	4 vs. 8–12 weeks	No differences of AIDS/death Lower in only CD4 <50 8 vs. 26 deaths/100 PYs	South Africa	ddI, 3TC, EFV
(2) CAMELIA Blanc et al. NEJM 2011 [42]	Smear +ve pulmonary TB	25	2 vs. 8 weeks	15 vs. 26 % 38 % lower in 2-week arm	Cambodia	d4T, 3TC, EFV
(3) STRIDE Havlir et al. NEJM 2011 [45]	Confirmed or probable pulmonary TB	77	<2 vs. 8–12 weeks	No differences of mortality Lower in only CD4 <50 15 vs. 27 %	Multi-national	TDF/FTC, EFV
(4) TOROK Torok et al. CID 2011 [49]	TB meningitis	41	<2 vs. 8 weeks	No differences of time to death	Vietnam	AZT, 3TC, EFV
(5) TIME Manosuthi et al. JAIDS 2012 [46]	Confirmed or probable any TB	43	4 vs. 12 weeks	Have a tendency in CD4 <50 10 vs. 14 deaths/100 PYs	Thailand	TDF, 3TC, EFV
(6) TB-HAART Mfinanga et al. Lancet ID 2014 [48]	Culture-confirmed TB	367	≤2 weeks vs. 6 months	No difference between early and late ART on composite endpoint of death, tuberculosis treatment failure, and recurrence	South Africa, Uganda, Zambia, Tanzania	AZT, 3TC, EFV

ISSN: 1742-6405